STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item		Page	Paragraph
mu	No	Recommendation		
Title and abstract	1	(a) Indicate the study's design with a commonly used term in	1	
		the title or the abstract		
		(b) Provide in the abstract an informative and balanced	2	
		summary of what was done and what was found		
Introduction				
Background/rationale	2	Explain the scientific background and rationale for the	3	1-2
		investigation being reported		
Objectives	3	State specific objectives, including any prespecified hypotheses	3	3
Methods				
Study design	4	Present key elements of study design early in the paper	4	1
Setting	5	Describe the setting, locations, and relevant dates, including	4-6	
		periods of recruitment, exposure, follow-up, and data collection		
Participants	6	(a) Give the eligibility criteria, and the sources and methods of	4	1
		selection of participants. Describe methods of follow-up		
		(b) For matched studies, give matching criteria and number of	N/A	
		exposed and unexposed		
Variables	7	Clearly define all outcomes, exposures, predictors, potential	4	1
		confounders, and effect modifiers. Give diagnostic criteria, if	5	1-2
		applicable	6	1-2
Data sources/	8*	For each variable of interest, give sources of data and details of	4	1
measurement		methods of assessment (measurement). Describe comparability	5	1-2
measurement		of assessment methods if there is more than one group	6	1-2
Bias	9	Describe any efforts to address potential sources of bias	7-8	2-4
Study size	10	Explain how the study size was arrived at	4	1
Quantitative	11	Explain how quantitative variables were handled in the	5	1
variables		analyses. If applicable, describe which groupings were chosen	6	2
		and why	7-8	1-4
Statistical methods	12	(a) Describe all statistical methods, including those used to	7 & 8	1-4
		control for confounding	, 66 6	
		(b) Describe any methods used to examine subgroups and	7 & 8	1-4
		interactions	7 & 0	1 1
		(c) Explain how missing data were addressed	5	2
		(d) If applicable, explain how loss to follow-up was addressed	9	Flowchart
		(e) Describe any sensitivity analyses	N/A	1 10 Wellart
		(E) Describe any sensitivity analyses	11/71	
Results	10:	() D		1
Participants	13*	(a) Report numbers of individuals at each stage of study—eg	4	1
		numbers potentially eligible, examined for eligibility,	9	Flowchart
		confirmed eligible, included in the study, completing follow-		
		up, and analysed		
		(b) Give reasons for non-participation at each stage	4	1
			9	Flowchart
		(c) Consider use of a flow diagram	9	Flowchart
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic,	9	1
		clinical, social) and information on exposures and potential	Table 1	
		confounders		

		(b) Indicate number of participants with missing data for each variable of interest	Table 1	
		(c) Summarise follow-up time (eg, average and total amount)	Table 1	-
Outcome data	15*	Report numbers of outcome events or summary measures over time	Table 1	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-	11-13	
		adjusted estimates and their precision (eg, 95% confidence	Table 2	2
		interval). Make clear which confounders were adjusted for and	Figure	1
		why they were included	Figure 2	
		(b) Report category boundaries when continuous variables were	5	2
		categorized	6	3
		(c) If relevant, consider translating estimates of relative risk	N/A	
		into absolute risk for a meaningful time period		
Other analyses	17	Report other analyses done—eg analyses of subgroups and	12	1
		interactions, and sensitivity analyses		
Discussion				
Key results	18	Summarise key results with reference to study objectives	16	1
Limitations	19	Discuss limitations of the study, taking into account sources of	18-19	2-3
		potential bias or imprecision. Discuss both direction and		
		magnitude of any potential bias		
Interpretation	20	Give a cautious overall interpretation of results considering	20	1
		objectives, limitations, multiplicity of analyses, results from		
		similar studies, and other relevant evidence		
Generalisability	21	Discuss the generalisability (external validity) of the study	17	4
		results	18-19	3
Other information				
Funding	22	Give the source of funding and the role of the funders for the	Provided in submission system	
		present study and, if applicable, for the original study on which		
		the present article is based		

^{*}Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at http://www.strobe-statement.org.